Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team

Hai-Sheng You,1,* Chun-Xia Gao,1,* Hai-Bin Wang,2 Sai-Sai Luo,1 Si-Ying Chen,1 Ya-Lin Dong,1 Jun Lyu,3 Tao Tian4 1Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 2Hangzhou Cognitive N&am...

Full description

Bibliographic Details
Main Authors: You HS, Gao CX, Wang HB, Luo SS, Chen SY, Dong YL, Lyu J, Tian T
Format: Article
Language:English
Published: Dove Medical Press 2020-03-01
Series:Cancer Management and Research
Subjects:
Online Access:https://www.dovepress.com/concordance-of-treatment-recommendations-for-metastatic-non-small-cell-peer-reviewed-article-CMAR
id doaj-8229868a39d34b699bf470040d8be19d
record_format Article
spelling doaj-8229868a39d34b699bf470040d8be19d2020-11-25T01:53:18ZengDove Medical PressCancer Management and Research1179-13222020-03-01Volume 121947195852509Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical TeamYou HSGao CXWang HBLuo SSChen SYDong YLLyu JTian THai-Sheng You,1,* Chun-Xia Gao,1,* Hai-Bin Wang,2 Sai-Sai Luo,1 Si-Ying Chen,1 Ya-Lin Dong,1 Jun Lyu,3 Tao Tian4 1Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 2Hangzhou Cognitive N&T. Co., Ltd, Hangzhou, Zhengjiang, People’s Republic of China; 3Clinical Research Center, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 4Department of Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China*These authors contributed equally to this workCorrespondence: Tao TianDepartment of Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, No. 277 West Yanta Road, Xi’an, Shaanxi 710061, People’s Republic of ChinaTel +86-13572206784Fax +86-29-85324086Email tiantao0607@163.comJun LyuClinical Research Center, The First Affiliated Hospital of Xi’an Jiaotong University, No. 277 West Yanta Road, Xi’an, Shaanxi 710061, People’s Republic of ChinaTel +86 29 8532 3614Fax +86 29 8532 3473Email lujun2006@xjtu.edu.cnObjective: The disease complexity of metastatic non-small-cell lung cancer (mNSCLC) makes it difficult for physicians to make clinical decisions efficiently and accurately. The Watson for Oncology (WFO) system of artificial intelligence might help physicians by providing fast and precise treatment regimens. This study measured the concordance of the medical treatment regimens of the WFO system and actual clinical regimens, with the aim of determining the suitability of WFO recommendations for Chinese patients with mNSCLC.Methods: Retrospective data of mNSCLC patients were input to the WFO, which generated a treatment regimen (WFO regimen). The actual regimen was made by physicians in a medical team for patients (medical-team regimen). The factors influencing the consistency of the two treatment options were analyzed by univariate and multivariate analyses.Results: The concordance rate was 85.16% between the WFO and medical-team regimens for mNSCLC patients. Logistic regression showed that the concordance differed significantly for various pathological types and gene mutations in two treatment regimens. Patients with adenocarcinoma had a lower rate of “recommended” regimen than those with squamous cell carcinoma. There was a statistically significant difference in EGFR-mutant patients for “not recommended” regimens with inconsistency rate of 18.75%. In conclusion, the WFO regimen has 85.16% consistency rate with medical-team regimen in our treatment center. The different pathological type and different gene mutation markedly influenced the agreement rate of the two treatment regimens.Conclusion: WFO recommendations have high applicability to mNSCLC patients in our hospital. This study demonstrates that the valuable WFO system may assist the doctors better to determine the accurate and effective treatment regimens for mNSCLC patients in the Chinese medical setting.Keywords: metastatic non-small-cell lung cancer, Watson for Oncology, concordance, artificial intelligence, treatment recommendationshttps://www.dovepress.com/concordance-of-treatment-recommendations-for-metastatic-non-small-cell-peer-reviewed-article-CMARmetastatic non-small-cell lung cancerwatson for oncologyconcordanceartificial intelligencetreatment recommendations
collection DOAJ
language English
format Article
sources DOAJ
author You HS
Gao CX
Wang HB
Luo SS
Chen SY
Dong YL
Lyu J
Tian T
spellingShingle You HS
Gao CX
Wang HB
Luo SS
Chen SY
Dong YL
Lyu J
Tian T
Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team
Cancer Management and Research
metastatic non-small-cell lung cancer
watson for oncology
concordance
artificial intelligence
treatment recommendations
author_facet You HS
Gao CX
Wang HB
Luo SS
Chen SY
Dong YL
Lyu J
Tian T
author_sort You HS
title Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team
title_short Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team
title_full Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team
title_fullStr Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team
title_full_unstemmed Concordance of Treatment Recommendations for Metastatic Non-Small-Cell Lung Cancer Between Watson for Oncology System and Medical Team
title_sort concordance of treatment recommendations for metastatic non-small-cell lung cancer between watson for oncology system and medical team
publisher Dove Medical Press
series Cancer Management and Research
issn 1179-1322
publishDate 2020-03-01
description Hai-Sheng You,1,* Chun-Xia Gao,1,* Hai-Bin Wang,2 Sai-Sai Luo,1 Si-Ying Chen,1 Ya-Lin Dong,1 Jun Lyu,3 Tao Tian4 1Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 2Hangzhou Cognitive N&T. Co., Ltd, Hangzhou, Zhengjiang, People’s Republic of China; 3Clinical Research Center, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 4Department of Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China*These authors contributed equally to this workCorrespondence: Tao TianDepartment of Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, No. 277 West Yanta Road, Xi’an, Shaanxi 710061, People’s Republic of ChinaTel +86-13572206784Fax +86-29-85324086Email tiantao0607@163.comJun LyuClinical Research Center, The First Affiliated Hospital of Xi’an Jiaotong University, No. 277 West Yanta Road, Xi’an, Shaanxi 710061, People’s Republic of ChinaTel +86 29 8532 3614Fax +86 29 8532 3473Email lujun2006@xjtu.edu.cnObjective: The disease complexity of metastatic non-small-cell lung cancer (mNSCLC) makes it difficult for physicians to make clinical decisions efficiently and accurately. The Watson for Oncology (WFO) system of artificial intelligence might help physicians by providing fast and precise treatment regimens. This study measured the concordance of the medical treatment regimens of the WFO system and actual clinical regimens, with the aim of determining the suitability of WFO recommendations for Chinese patients with mNSCLC.Methods: Retrospective data of mNSCLC patients were input to the WFO, which generated a treatment regimen (WFO regimen). The actual regimen was made by physicians in a medical team for patients (medical-team regimen). The factors influencing the consistency of the two treatment options were analyzed by univariate and multivariate analyses.Results: The concordance rate was 85.16% between the WFO and medical-team regimens for mNSCLC patients. Logistic regression showed that the concordance differed significantly for various pathological types and gene mutations in two treatment regimens. Patients with adenocarcinoma had a lower rate of “recommended” regimen than those with squamous cell carcinoma. There was a statistically significant difference in EGFR-mutant patients for “not recommended” regimens with inconsistency rate of 18.75%. In conclusion, the WFO regimen has 85.16% consistency rate with medical-team regimen in our treatment center. The different pathological type and different gene mutation markedly influenced the agreement rate of the two treatment regimens.Conclusion: WFO recommendations have high applicability to mNSCLC patients in our hospital. This study demonstrates that the valuable WFO system may assist the doctors better to determine the accurate and effective treatment regimens for mNSCLC patients in the Chinese medical setting.Keywords: metastatic non-small-cell lung cancer, Watson for Oncology, concordance, artificial intelligence, treatment recommendations
topic metastatic non-small-cell lung cancer
watson for oncology
concordance
artificial intelligence
treatment recommendations
url https://www.dovepress.com/concordance-of-treatment-recommendations-for-metastatic-non-small-cell-peer-reviewed-article-CMAR
work_keys_str_mv AT youhs concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam
AT gaocx concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam
AT wanghb concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam
AT luoss concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam
AT chensy concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam
AT dongyl concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam
AT lyuj concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam
AT tiant concordanceoftreatmentrecommendationsformetastaticnonsmallcelllungcancerbetweenwatsonforoncologysystemandmedicalteam
_version_ 1724991807392055296